Opinion
Video
Clinical Impact of IgA Nephropathy and Quality of Life
Panelists discuss how immunoglobulin A (IgA) nephropathy significantly impacts patients’ quality of life through chronic symptoms, treatment burden, psychological effects, and the looming threat of progressive kidney function decline.
Clinical Impact and Quality of Life in IgA Nephropathy
Disease Burden and Progression
- Progressive kidney disease: 30%-40% of patients develop end-stage kidney disease (ESKD) within 20-30 years of diagnosis
- Variable progression rate: Some patients experience rapid decline in kidney function (5%-10%), while others have stable disease for decades
- Hypertension development: Affects 60%-80% of patients during disease course, requiring long-term management
- Proteinuria burden: Persistent proteinuria > 1g/day significantly increases risk of progression to ESKD
- Recurrent gross hematuria: Episodes may cause acute kidney injury and temporary functional impairment
Quality of Life Impact
- Symptom burden:
- Fatigue and reduced energy levels, particularly with advancing chronic kidney disease (CKD)
- Sleep disturbances and insomnia
- Edema and physical discomfort in those with significant proteinuria
- Pain during hematuria episodes
- Psychological effects:
- Anxiety related to uncertain disease prognosis
- Depression, particularly in patients with progressive disease
- Stress surrounding family planning and genetic concerns
- Fear of dialysis and transplantation
- Treatment-related challenges:
- Medication adverse effects, especially with immunosuppressive therapies
- Dietary restrictions (sodium, protein) affecting social dining
- Frequent medical appointments disrupting work and personal life
- Financial burden of chronic disease management
- Functional limitations:
- Reduced physical capacity with advancing CKD
- Work productivity and employment challenges
- Limitations in physical activities during hematuria episodes
- Travel restrictions, particularly with advanced disease
Special Considerations
- Young adult onset: Disease typically affects individuals during prime educational, career, and family-building years
- Lifelong management: Need for ongoing monitoring and medication adherence
- Transplant concerns: Disease recurrence posttransplantation (30%-35%)
- Socioeconomic impact: Work absences, disability, and health care costs
- Transition challenges: Pediatric to adult care transitions for early-onset cases
Early intervention focusing on both disease-modifying therapies and quality of life improvements is essential for comprehensive management of IgA nephropathy. Patient education, psychosocial support, and attention to symptom management should complement efforts to preserve kidney function.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
